Oncotelic Therapeutics, INC

Oncotelic Therapeutics, Inc. filed an 8-K report detailing a corporate presentation given to employees, directors, officers, and advisors on July 13, 2026.

Oncotelic Therapeutics announced the grant of 17,796 Restricted Stock Units (RSUs) to directors, officers, employees, and advisors, tied to a stock exchange uplisting.

Oncotelic Therapeutics, Inc. has entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note and commitment shares to raise $178,410.

Oncotelic Therapeutics, Inc. announced the completion of a merger involving its subsidiary Oncotelic Inc. and Lunai Bioworks, Inc., resulting in the acquisition of significant intellectual property assets.

Oncotelic Therapeutics reported a $249 million net income for fiscal year 2025, driven primarily by a non-cash fair value increase in its GMP Biotechnology joint venture investment.

Oncotelic Therapeutics has entered a joint development agreement with TechForce Robotics to commercialize an AI-enabled, GMP-compliant robotic system for pharmaceutical manufacturing.

Oncotelic Therapeutics reports Q1 2026 financial results, highlighting ongoing joint venture developments and new strategic partnerships in AI-enabled robotics.

Oncotelic Therapeutics reports a reduced net loss for Q3 2025, driven by the absence of goodwill impairment, while its GMP Bio joint venture advances drug pipeline and targets a 2026 Hong Kong IPO.

Oncotelic Therapeutics, Inc. reported a net income for Q2 2025 and reduced its six-month net loss, but continues to face substantial doubt about its ability to continue as a going concern due to significant accumulated losses and negative working capital.

Oncotelic Therapeutics files its Form 10-Q for the quarter ended March 31, 2025, detailing its financial results and business activities.

Oncotelic Therapeutics reported a net loss for Q3 2024, impacted by a significant goodwill impairment and ongoing operational expenses, while highlighting its joint venture progress and financial restructuring efforts.

Oncotelic Therapeutics reported its second quarter 2024 results, highlighting ongoing drug development efforts and financial challenges including a going concern warning.

Oncotelic Therapeutics, Inc. (OTLC) filed its annual report for the fiscal year ended December 31, 2025, highlighting a significant increase in the fair value of its investment in its joint venture, GMP Biotechnology Limited (GMP Bio).

Oncotelic Therapeutics' 2024 annual report details ongoing efforts to develop cancer treatments, manage financial constraints, and advance strategic partnerships, particularly through its joint venture GMP Biotechnology.

Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, announced its financial results for the year ended December 31, 2023, highlighting progress in its joint venture and ongoing development programs.

Seymour Howard Fein, CRO/CMO of Oncotelic Therapeutics, Inc., received 250 shares of common stock on July 10, 2026.

Steven W King, a Director of Oncotelic Therapeutics, Inc., received 250 shares of common stock on July 10, 2026.

Anthony E Maida Iii, DIRECTOR AND CMO - TRANS. MED. and a Director of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.

Saran Saund, CBO of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.

Amit B. Shah, CFO of Oncotelic Therapeutics, Inc., received 1,500 shares of common stock on July 10, 2026.

Vuong Trieu, CHAIRMAN AND CEO, a Director and 10% owner of Oncotelic Therapeutics, Inc., received 2,000 shares of common stock on July 10, 2026.

Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1/A registration statement for the resale of 115.6 million common shares by Mast Hill Fund, LP, while continuing to face substantial doubt about its ability to continue as a going concern.

Oncotelic Therapeutics files S-1 for resale of 309.7 million shares by Mast Hill Fund, highlighting significant dilution and ongoing financial challenges despite pipeline progress.